Adult ADHD Treatment: What the 2025 Evidence Actually Shows
- 6 days ago
- 2 min read
Adult ADHD treatment discussions often collapse into slogans: medication works, therapy works, stimulants are best, medication is overused, coaching fixes executive function. A large 2025 analysis offers a more useful answer: some conclusions are reasonably supported, and many broader questions remain unsettled.
The study
Researchers analyzed 113 randomized controlled trials involving 14,887 adults. The trials included pharmacological treatments, psychological interventions, neurostimulation or neurofeedback, and control conditions.
The clearest short-term finding
At timepoints closest to 12 weeks, stimulants and atomoxetine were the only interventions with evidence of benefit for core ADHD symptoms supported by both self-reported and clinician-reported ratings. Atomoxetine showed lower acceptability than placebo on all-cause discontinuation in the network analysis.
Several non-pharmacological approaches showed benefit on clinician-rated symptoms but not self-rated symptoms, producing less consistent evidence across raters.
The strongest evidence was for short-term core symptoms. That is narrower than “this treatment fixes adult ADHD.”
What the evidence was weaker on
Longer-term evidence was much thinner. The authors also emphasized that broader outcomes such as quality of life were not clearly improved by ADHD medications in the available adult trials.
That distinction matters clinically. Symptom reduction is important, but patients usually care about whether work, school, relationships, sleep, time management, and daily functioning actually improve.
What this means in practice
Evidence informs treatment selection; it does not choose treatment for an individual patient. Medical history, prior response, side effects, comorbid conditions, functional goals, patient preference, and monitoring all matter.
It also argues for follow-up that measures more than whether someone “feels more focused.” The meaningful question is whether the target problems are improving without creating unacceptable tradeoffs.